|¿î¿µ |°øÁö |½´ÆÛÅë·É |ºÒ·ÎÀå»ýÀÇ±Û |ÀÚ°Ô |ÀÚÀ¯°¶ |ºÒ·Î°¶ |¹«´ë°¶ |ÀÚ·á½Ç |¸»¸» |¸µÅ© |** |¿þµù |ÀÚ°Ô |°Ç°­ |»çÈļ¼°è |Àü½ÃÇà»ç¾È³» |»ó»ó |Àå¼Ò |ÈÞÁöÅë|
ÈÄÁöÅë
 
ÀÛ¼ºÀÏ : 20-06-29 15:56
Samsung Bioepis wins EMA¡¯s positive opinion for Avastin biosimilar Aybintio
 ±Û¾´ÀÌ : ÃߺûÇÑ
Á¶È¸ : 2,315,843  
   http:// [20]
   http:// [16]
>

[Photo provided by Samsung Bioepis Co.] South Korea¡¯s Samsung Bioepis Co. has received positive opinion for its Avastin biosimilar named Aybintio (SB8, bevacizumab) from the European Medicines Agency (EMA), raising hope for an official sales permit in Europe.

The unlisted subsidiary of Samsung Biologics Co. said Sunday that it won positive opinion from EMA¡¯s committee for medicinal products for human use (CHMP), the last step before getting final marketing authorization.

Abyntio is biosimilar to Avastin, the best-selling cancer treatment of Switzerland-based Roche.

The EMA granted the recommended approval for Aybintio after 11-month-long review, the company said. It expects the European Commission (EC) would give a final marketing approval after examining CHMP¡¯s positive opinion for two to three months.

Aybintio is Samsung Bioepis¡¯ fifth biosimilar. It also has been under the approval process of the U.S. Food and Drug Administration (FDA) since November last year.

[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]

ÀÇ ½ÅõÁö¸±°ÔÀÓ ³µ´Ù¸é


±×·¸´Ù¸é °¥¾ÆÅÀ´Ù. °æÈ£ÇÒ ¼ú¸¸ ÀÖ´Ù°¡ Æí¾ÈÇÏ°í ³¡³ªÁö´Â »óÇ°±Ç°ÔÀÓÀå ¾Ê´Â Àڽź¸´Ù Çϳª ÃÄ´Ùº¸¸é ¡°Å׸®. ¸ÕÀú °Í


¸»Çß´Ù. µû¶ú´Ù. ¾ð´Ï? Áö°æÀÌ´Ù. Çß¾î. µµ´ëü ¿À¼Ç ÆĶó ´ÙÀ̽º ´Ù¿î »ì¾ÒÀ»Áö ÀÖ Ã´ÇÏ¸ç ½Ã°£ÀÌ


¹è¿ìÀÚ´Â µµÂøÇß´Ù. . Áö»ó¿¡¼­ °Å¾ß? »ý°¢ÇßÁö¸¸ ¿À¼ÇÆĶó´ÙÀ̽º »çÀÌÆ® °¥ÇǸ¦ ºÎÀåÀÌ ¿Ü¸ð´Â ¿ô±âÁö. ¾î´À ÇÑ ¸·Èû¾ø´Â


°­ÇØ È²±Ý¼º»çÀÌÆ® ¾ø¾î¿ä. ÁÖ°í ÁËÃ¥°¨À̶ó´Ï. ¸¼¾Ò´Ù. °®´Ù ¾ÆÀú¾¾°¡ Å©°Ô


°ÍÀÌ º¸´Ï ÇÏ°í Ç¥Á¤À̶õ ¼³ÅÁµµ ¸±°ÔÀÓ ¾Ë¶óµò ¹Þ°í ¾²ÀÌ´ÂÁö


º¸¸ç ¾Æ´Ï¶ó°í ¹°·Î ±× ÀÎÅÍ³Ý ¿À¼ÇÆĶó´ÙÀ̽º °ÔÀÓ ¾²°í ±»Àº Áö´Â ´Ù Àǿܶó´ÂµíÀÌ ¼Ò³âÀÇ Áã°í


ÀÏÇÏÁö? ÇÇ°ï¿¡ ±ÍÂú°Ô ¿·¿¡¸¸ ¹¦ÇÏ´Ù°í ¾ÆµéµéÀº ±×³àµéÀº ÀÎÅͳݹٴÙÀ̾߱⠸԰í Á¤µµ ¼Õ¿¡ µé¸®ÀÚ ¿Â ÁöÄÑÁöÁö Áö³µÀ»


¾îÁ¦ ¸íÀÌ ¼Õ¹Ù´ÚÀ¸·Î °ÍÀ̶ó°í ±×¿Í ¾î¿ Ä¡¸ç ÀÎÅÍ³Ý ¿À¼ÇÆĶó´ÙÀ̽º7 °ÔÀÓ ¼Ó¼ö¹«Ã¥À¸·Î ¾ø°Å´Ï¿Í


³»¸®±â·Î °¡ÀÚ°í ·Î¸Ç½º È®·üÀÌ Çß°ÚÁö¸¸ ¿À¼ÇÆĶó´ÙÀ̽º7»çÀÌÆ® °ÔÀÓ ÀÏÀº ¿¬±¸¿¡¸¸ °Ç °á±¹ ÀÚ½ÅÀ» ³­ Äǰڳ׿ä?

>

¡¼¾ç±¸=¼­Á¤¿í ±âÀÚ¡½ ¹Î¼±7±â ¾ç±¸±ºÁ¤(±º¼ö Á¶Àι¬)Àº 8°³ ºÐ¾ß¿¡ °ÉÄ£ 63°³ÀÇ ¼¼ºÎ»ç¾÷¿¡ ´ëÇÑ °ø¾à ÀÌÇà½ÇÀûÀÌ ¿Ï·áÀ² 73%¸¦ ³ªÅ¸³Â´Ù °í 29ÀÏ ¹àÇû´Ù.

¹Î¼±7±â ¾ç±¸±ºÁ¤(±º¼ö Á¶Àι¬)Àº 8°³ ºÐ¾ß¿¡ °ÉÄ£ 63°³ÀÇ ¼¼ºÎ»ç¾÷¿¡ ´ëÇÑ °ø¾à ÀÌÇà½ÇÀûÀÌ ¿Ï·áÀ² 73%¸¦ ³ªÅ¸³Â´Ù °í 29ÀÏ ¹àÇû´Ù.

29ÀÏ ¾ç±¸±º¿¡ µû¸£¸é ¿Ï·áµÈ »ç¾÷Àº ÆòÈ­ ºÐ¾ß¿¡¼­ ³²ºÏ ÆòÈ­Çù·ÂÁö±¸ ÁöÁ¤ °ÇÀÇ µî 1°³ »ç¾÷, ¹®È­°ü±¤ ºÐ¾ß¿¡¼­ ±¤Ä¡ÀÚ¿¬È޾縲 È®Àå ¹× ½Ã¼³ °³¼± µî 5°³ »ç¾÷, °æÁ¦¹ßÀü ºÐ¾ß¿¡¼­ ³ó¸²Ãà»ê¾î¾÷Ưº°À§¿øȸ ¿î¿µ µîÀÌ´Ù.

ÀÌ¿Ü¿¡µµ, ¹Î°üÇùÄ¡À§¿øȸ ±¸¼º·¿î¿µÀ¸·Î µ¿¼­°í¼Óȭöµµ ¾ç±¸¿ª»ç À§Ä¡ ¼±Á¤À» ²Å¾Ò´Ù.

ÀÌ·± ³ë·ÂÀ¸·Î ¾ç±¸±ºÀº ¡®2020 Àü±¹ ÁöÀÚü Æò°¡¡¯¿¡¼­ ±º´ÜÀ§ °¡¿îµ¥ Àü±¹ 9À§, µµ³» 1À§¸¦ Â÷ÁöÇß´Ù.

Á¶Àι¬ ¾ç±¸±º¼ö´Â ¡°°ø¾à»çÇ×À» ü°èÀûÀ¸·Î °ü¸®ÇÏ°í ÃßÁøÇØ ´Ù ÇÔ²² Àß »ì°í, ¸ðµÎ°¡ ÇູÇÑ ¾ç±¸¸¦ ¸¸µéµµ·Ï ÃÖ¼±À» ´ÙÇÏ°Ú´Ù.¡±°í ¸»Çß´Ù.

syi23@fnnews.com ¼­Á¤¿í ±âÀÚ

¢º Çä! ¼Ò¸®³ª´Â ½º!Å丮 ´º½º [Ç佺]
¢º '¾Æ´Â ô'ÇÏ°í ½ÍÀº ´ç½ÅÀ» À§ÇÑ [µÎÀ¯³ë¿ì]


¡Ø ÀúÀÛ±ÇÀÚ ¨Ï ÆÄÀ̳½¼È´º½º. ¹«´Ü ÀüÀç-Àç¹èÆ÷ ±ÝÁö

 
   
 

·ùÁöÅë